Related references
Note: Only part of the references are listed.ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization
Jiaren Mao et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)
ASPP1 deficiency promotes epithelial-mesenchymal transition, invasion and metastasis in colorectal cancer
Dian Liu et al.
CELL DEATH & DISEASE (2020)
Breast cancer: Biology, biomarkers, and treatments
Khadijeh Barzaman et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Apoptosis stimulating protein of p53 (ASPP) 1 and ASPP2 m-RNA expression in oral cancer
Kinjal D. Patel et al.
ARCHIVES OF ORAL BIOLOGY (2020)
Overexpression of iASPP is required for autophagy in response to oxidative stress in choriocarcinoma
Ka-Kui Chan et al.
BMC CANCER (2019)
ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma
Tongwang Yang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
iASPP-PP1 complex is required for cytokinetic abscission by controlling CEP55 dephosphorylation
Kun Gao et al.
CELL DEATH & DISEASE (2018)
Expression pattern of the apoptosis-stimulating protein of p53 family in p53+ human breast cancer cell lines
Changsong Wang et al.
CANCER CELL INTERNATIONAL (2013)
Elevated expression of iASPP correlates with poor prognosis and chemoresistance/radioresistance in FIGO Ib1-IIa squamous cell cervical cancer
Liping Cao et al.
CELL AND TISSUE RESEARCH (2013)
ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells
Y. Wang et al.
CELL DEATH AND DIFFERENTIATION (2013)
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Scott Valastyan et al.
CELL (2011)
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
Herve Bonnefoi et al.
LANCET ONCOLOGY (2011)
TP53 mutations in human cancers:: functional selection and impact on cancer prognosis and outcomes
A. Petitjean et al.
ONCOGENE (2007)
ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia
X Agirre et al.
ONCOGENE (2006)
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
M Olivier et al.
CLINICAL CANCER RESEARCH (2006)
Abnormal mRNA expression of ASPP members in leukemia cell lines
ZJ Liu et al.
LEUKEMIA (2004)
Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: Correlation with clinical outcome
IS Lossos et al.
LEUKEMIA & LYMPHOMA (2002)
ASPP proteins specifically stimulate the apoptotic function of p53
Y Samuels-Lev et al.
MOLECULAR CELL (2001)
Share Paper
